ARCHIVES

Carfilzomib Demonstrates Clinical Benefit Rate of 64%

This article is from The Cancer Letter archive.

Vol. 34 No. 12 | December 30, 2011

Download PDF Visit The Full Archive

Related Articles

Northwestern, Rochester, Howard First In Line For Limited Construction Funds

August 20, 1976

ASCO Awards Contract For D.C Office

January 12, 1990

DeVita Swearing In Schedule Aug. 8

August 1, 1980

Alcohol Consumption Increases Risk Of Lobular And HR+ Breast Cancer

August 27, 2010

Rituximab and Fludarabine Combination Produces Long-Term Remissions in CLL

March 25, 2011

Litton’s Government Contracts Status Under Review

September 6, 1985